Literature DB >> 856462

Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

R S Benjamin, C E Riggs, N R Bachur.   

Abstract

A new, nondestructive, plasma extraction technique ultilizing chloroform:isopropyl alcohol (1:1) and ammonium sulfate saturation has been devised to isolate adriamycin and its metabolites from human plasma. Adriamycin was the most prominent species in plasma. It disappeared according to a triphasic pattern with a mean half-life of 30 hr. Six metabolites have been clearly separated from adriamycin by thin-layer chromatography. Three were aglycones and three were polar metabolites, one of which has been identified as adriamycinol. All metabolites appeared rapidly in plasma and disappeared according to a biphasic or tri-phasic pattern. The polar metabolites in plasma were found in similar relative concentration to those in urine. In contrast to the small Quantities of aglycones in urine, however, significant concentrations of aglycones were found in plasma. The least prominent metabolite was adriamycin aglycone; the most prominent metabolite was a less polar aglycone, most likely deoxyadriamycin aglycone, and a more polar aglycone, presumably demethyl deoxyadriamycinol aglycone, was the only metabolite to show variable pharmacokinetics in different patients. The nondestructive plasma extraction technique has verified the presence of extensive human metabolism of adriamycin and demonstrated the presence of aglycone and polar metabolites.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856462

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Failure of liver function tests in predicting drug clearance of chemotherapeutic agents in a patient who had recovered from hepatic congestion.

Authors:  Masaharu Tsubokura; Yuji Miura; Tatsuo Itokawa; Naoko Takei; Tadanao Higaki; Toshihiro Amaki; Yasuo Ishida; Makiko Kusama; Shunsuke Ono; Hiroto Narimatsu; Masahiro Kami; Tsunehiko Komatsu
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

2.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Cardiotoxic effects of anthracyclines.

Authors:  M R Bristow
Journal:  West J Med       Date:  1983-09

5.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

6.  Plasma kinetics of aclacinomycin A and its major metabolites in man.

Authors:  M J Egorin; D Van Echo; B M Fox; M Whitacre; N R Bachur
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.

Authors:  H Iguchi; H Tone; T Ishikura; T Takeuchi; H Umezawa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  CCNU-adriamycin association induces earlier and more severe nephropathy in rats.

Authors:  G Raguenez-Viotte; M Lahoue; T Ducastelle; J P Morin; J P Fillastre
Journal:  Arch Toxicol       Date:  1988       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.